About
About Human Metabolome Technologies, Inc
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Visit company website
5 years, 5 months ago
Human Metabolome Technologies, Inc is currently in a long term downtrend where the price is trading 0.6% below its 200 day moving average.
From a valuation standpoint, the stock is 93.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.
Human Metabolome Technologies, Inc's total revenue rose by 13.8% to $292M since the same quarter in the previous year.
Its net income has increased by 198.7% to $30M since the same quarter in the previous year.
Based on the above factors, Human Metabolome Technologies, Inc gets an overall score of 3/5.